amifostine anhydrous has been researched along with Deglutition Disorders in 7 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Deglutition Disorders: Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies." | 2.71 | Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. ( Axelrod, R; Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Scott, C; Smith, C; Wasserman, T; Werner-Wasik, M, 2005) |
| "radiotherapy plus amifostine for cancer treatment." | 2.43 | Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. ( Clark, LG; Clark, OA; Sasse, AD; Sasse, EC, 2006) |
| "Radiation for head and neck cancers is often curative, but high doses are used." | 2.43 | How to reduce radiation-related toxicity in patients with cancer of the head and neck. ( Chambers, MS; Garden, AS; Lewin, JS, 2006) |
| "Radiation-induced esophagitis is a frequent acute side effect in curative and palliative radiotherapy of thoracal and cervical tumors." | 2.40 | Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus. ( Feldmann, HJ; Geinitz, H; Zimmermann, FB, 1998) |
| "Xerostomia has been seen in 15 patients (Grade I) and 5 patients (Grade II) after administration of amifostine." | 1.30 | Amifostine--a radioprotector in locally advanced head and neck tumors. ( Prott, FJ; Schönekäs, KG; Wagner, W, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Movsas, B | 1 |
| Scott, C | 1 |
| Langer, C | 1 |
| Werner-Wasik, M | 1 |
| Nicolaou, N | 1 |
| Komaki, R | 1 |
| Machtay, M | 1 |
| Smith, C | 1 |
| Axelrod, R | 1 |
| Sarna, L | 1 |
| Wasserman, T | 1 |
| Byhardt, R | 1 |
| Sasse, AD | 1 |
| Clark, LG | 1 |
| Sasse, EC | 1 |
| Clark, OA | 1 |
| Garden, AS | 1 |
| Lewin, JS | 1 |
| Chambers, MS | 1 |
| Zimmermann, FB | 1 |
| Geinitz, H | 1 |
| Feldmann, HJ | 1 |
| Schönekäs, KG | 1 |
| Wagner, W | 1 |
| Prott, FJ | 1 |
| Büntzel, J | 1 |
| Glatzel, M | 1 |
| Schuth, J | 1 |
| Weinaug, R | 1 |
| Küttner, K | 1 |
| Fröhlich, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitax[NCT00003313] | Phase 3 | 243 participants (Actual) | Interventional | 1998-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for amifostine anhydrous and Deglutition Disorders
| Article | Year |
|---|---|
Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
Topics: Amifostine; Cystitis; Deglutition Disorders; Esophagitis; Humans; Neoplasms; Radiation Injuries; Rad | 2006 |
How to reduce radiation-related toxicity in patients with cancer of the head and neck.
Topics: Amifostine; Anti-Infective Agents; Deglutition Disorders; Fibrosis; Free Radical Scavengers; Growth | 2006 |
Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus.
Topics: Amifostine; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Deglutition Diso | 1998 |
1 trial available for amifostine anhydrous and Deglutition Disorders
| Article | Year |
|---|---|
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small- | 2005 |
3 other studies available for amifostine anhydrous and Deglutition Disorders
| Article | Year |
|---|---|
Chemoradiotherapy for head and neck cancer: 'local' side effects are actually systemic.
Topics: Amifostine; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deglutition Di | 2006 |
Amifostine--a radioprotector in locally advanced head and neck tumors.
Topics: Adult; Aged; Amifostine; Deglutition Disorders; Female; Head and Neck Neoplasms; Humans; Male; Middl | 1999 |
[Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Topics: Adult; Aged; Amifostine; Anemia; Antineoplastic Agents; Brachytherapy; Carboplatin; Combined Modalit | 1999 |